Macrophage colony stimulating factor inhibits experimental liver metastases from colon cancer.
This study investigated the inhibitory effect of human macrophage colony stimulating factor (hM-CSF) on experimental liver metastases. Murine colon cancer cell lines C-26 and C-36 were each injected into the spleen of BALB/c mice and the number of subsequent liver metastases was counted. An optimal dose (3,000U/body/day) of hM-CSF to inhibit liver metastases was identified. Additionally, hM-CSF (3,000U/body/day) administration for 7 days before and after the injection of the same cancer cell lines was investigated. The mean number of liver metastases decreased significantly in the hM-CSF group compared with the saline group. These results suggest potential therapeutic benefit for the use of hM-CSF in the adjuvant treatment of liver metastases.
Sasaki
K
K
First Department of Surgery, Sapporo Medical University, School of Medicine, Japan.
Hirata
K
K
Torimoto
K
K
Sakawaki
T
T
Nakamura
M
M
Sato
N
N
Kikuchi
K
K
D000818:Animals; D003110:Colonic Neoplasms / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control* / Q000556:secondary*; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C
D016179:Granulocyte Colony-Stimulating Factor; D016173:Macrophage Colony-Stimulating Factor